Clinical Research Directory
Browse clinical research sites, groups, and studies.
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
The primary objective was to evaluate the effect of PCSK9 inhibitors in addition to the background lipid-modifying therapy (LMT), compared with standard LMT in terms of clinical outcomes in patients with coronary CT angiography (CCTA)-detected high-risk plaques.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3596
Start Date
2025-04-22
Completion Date
2033-04
Last Updated
2026-02-06
Healthy Volunteers
No
Interventions
PCSK9 inhibitors and background lipid-modifying therapy
Patients will receive subcutaneous injections of PCSK9 inhibitors and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with PCSK9 inhibitors administered every 2 weeks. After the first 12 months, patients will discontinue the PCSK9 inhibitors but continue background LMT for the remainder of the trial.
Standard lipid-modifying therapy
Patients will receive standard LMT commonly used in clinical practice.
Locations (6)
Zhejiang Provincial Hospital of Traditional Chinese Medicine
Hangzhou, Zhejiang, China
Hangzhou Linping First People's Hospital
Hangzhou, China
The Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China
Zhejiang Hospital
Hangzhou, China
Jinhua Central Hospital
Jinhua, China
Seoul National University Hospital
Seoul, South Korea